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Research Brief
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National stewardship guidelines recommend that hospitals develop
interventions to increase use of oral antibiotics.1 Transition from
intravenous to oral route of administration for antibiotics with high
oral bioavailability (HOB) is a simple intervention shown to
decrease cost and length of hospitalization. We sought to determine
the prevalence of use and route of administration of HOB antibiotics at children’s hospitals to determine how frequently intravenous to oral switch might be feasible and to quantify potential
cost savings of this strategy in hospitalized children.

HOB antibiotic DOT that were administered orally (% PO DOT)
and (2) the percentage of all patients receiving HOB antibiotics
who received doses orally, either completely or in combination
with intravenous therapy. If children received antibiotic doses via
both routes on the same day it was counted as an oral DOT.
Specific diagnoses were identified using All Patient Refined
Diagnosis Related Groups (APR-DRGs).
Antibiotic costs were estimated using institution-specific costto-charge ratios. Maximal cost-savings were estimated using the
same institution-specific cost-to-charge ratios under the alternate
case of administering all doses of HOB antibiotics orally.

Methods
We used 2015 data from the Pediatric Health Information System
(PHIS), an administrative and clinical database maintained by the
Children’s Hospital Association.2 Patients were included if they
were potentially eligible for intravenous to oral switch as defined
by (1) receipt of an HOB antibiotic, (2) receipt of ≥1 nonantibiotic
oral medication on the same day as the antibiotic, and (3) hospital stay
>2 days. The HOB antibiotics included clindamycin, metronidazole,
ciprofloxacin, levofloxacin, doxycycline, linezolid and rifampin, all of
which have ≥80% oral bioavailability.3 Antimicrobials typically used
for prophylaxis (azithromycin, trimethoprim-sulfamethoxazole, and
azoles) were excluded because they are usually given orally and it is
difficult to distinguish treatment from prophylaxis using PHIS data.
Days of therapy (DOT) for each drug were reported overall
and stratified by route and hospital. Oral administration of HOB
antibiotics was reported using 2 metrics: (1) the percentage of all
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Results
Data from 48 freestanding children’s hospitals were included:
38,933 children received 221,535 DOT of HOB antibiotics and at
least 1 nonantibiotic oral medication, accounting for ~17% of all
PHIS antibiotic use. Overall, 35.8% of all HOB DOT were
administered orally, ranging from 21.3% to 63.8% across institutions. Clindamycin was the most commonly prescribed HOB
antibiotic, accounting for nearly half of all HOB DOT (Table 1).
However, it had the lowest percentage of oral DOT (21.7%) and the
highest percentage (63.0%) of intravenous-only receipt. Cellulitis
was the most common diagnosis associated with clindamycin use,
for which 27.6% of DOT were oral. Other common diagnoses
included pneumonia (26% oral DOT) and musculoskeletal infections (16% oral DOT).
The HOB antibiotics most likely to be prescribed orally were
rifampin (80.5% of all DOT) and doxycycline (70.8% of all DOT).
Fluoroquinolones were administered orally for only half of all
DOT. However, there was significant variation in the proportion
of oral fluoroquinolone use across institutions, ranging from
27.0% to 98.3% for ciprofloxacin and from 0 to 100% for levofloxacin. Similarly, less than one-third of linezolid DOT were
administered orally, ranging from 0 to 100% across institutions.
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Table 1. Prevalence of High Oral Bioavailability Antibiotic Use and Proportion of Oral Administration
Route of Antibiotic Administration, % Patients
Drug

DOT

% PO DOT Overall

Min %

Max %

No. of Patients

PO Only

IV Only

Both

102,628

21.7

4.7

65.7

21,956

9.1

63.0

27.9

Metronidazole

52,478

38.4

12.3

71.7

10,270

32.1

53.0

15.0

Ciprofloxacin

26,125

55.1

27.0

98.3

5,480

53.9

29.8

16.3

Levofloxacin

14,341

50.4

0.0

100.0

2,496

48.6

34.6

16.8

Linezolid

9,820

30.8

0.0

100.0

1,644

32.3

54.3

13.4

Doxycycline

8,189

70.8

29.6

98.3

1,522

61.2

20.8

17.9

Rifampin

7,954

80.5

0.0

100.0

998

75.3

12.8

11.9

221,535

35.8

21.3

63.8

38,993

22.9

50.8

26.3

Clindamycin

Overall

Note. PO, per oral; DOT, days of therapy; Min %, % PO DOT at hospital with lowest % PO DOT for each drug; Max %, % PO DOT at hospital with highest % PO DOT for each drug; IV,
intravenous.

The total hospital cost for all HOB antibiotics administered
during the study period was $11,662,963. The estimated cost had
all doses been administered orally was $5,891,137.

Discussion
Only 36% of HOB antibiotic DOT were administered orally in
this cohort of children receiving other oral medications. These
data suggest that intravenous to oral switch programs should be
prioritized in children’s hospitals. Clindamycin should be a priority
target for such programs because it is both commonly used and often
administered intravenously. It is well-documented that intravenous to
oral switch is safe and effective for children with osteomyelitis4,5 and
complicated pneumonia,6 2 common indications for clindamycin.
However, in this cohort, children with these diagnoses were more
likely to be treated with intravenous clindamycin.
Intravenous to oral switch programs would be cost saving in
pediatrics. We estimated a nearly 50% decrease in drug cost alone.
Although this represents the maximum potential savings in direct
drug costs, it does not account for additional cost savings due to
drug administration, shorter hospital stays, avoidance of outpatient
parenteral antibiotic therapy and catheter-associated infections.
The reasons for underutilization of oral administration are
uncertain. Some clinicians and parents may have the perception
that intravenous antibiotics are more effective7 or that insurance
companies mandate intravenous therapy for reimbursement of
hospitalization. Future studies should focus on differences in
clinical outcomes between children who received HOB antibiotics
via oral as compared to intravenous routes.
This analysis has several limitations. We utilized administrative data to identify children eligible for oral conversion.
Although this approach has been used in other studies,8 we could
not account for patient factors such as severity of illness or
intolerance of oral antibiotics, though inclusion in this cohort
required receipt of another oral medication. We did not exclude
diagnoses that mandate intravenous therapy such as endovascular or central nervous system infections. However, it is unlikely that differences in the prevalence of these infections would
explain more than a minority of the variation in use of oral
antibiotic across hospitals. Finally, because PHIS only includes
data from freestanding children’s hospitals, most of which have

formal ASPs,9 these results may not be generalizable to other
settings.
In conclusion, we observed frequent intravenous administration of HOB antibiotics at children’s hospitals. Intravenous to oral
conversion programs, with a focus on clindamycin and fluoroquinolones, are potential high-impact targets for antimicrobial
stewardship.
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